X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Shanghai COVID Cases Result In More Harsh Citywide Closures

Content Team by Content Team
18th April 2022
in News
Shanghai COVID Cases Result In More Harsh Citywide Closures

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

On April 16th, Shanghai reported a new high for symptomatic COVID-19 cases, while other cities throughout China tightened controls as the country continued its “dynamic clearing” strategy to eradicate the highly communicable Omicron form.

A day before, the Zhengzhou Airport Economic Zone, one of the central Chinese manufacturing areas where Apple Inc. supplier Foxconn is located, issued a 14-day lockdown “to be adjusted according to the pandemic scenario.”

Following hundreds of COVID-19 infections this month, the city of Xian in northwest China recommended citizens avoid needless visits beyond their residential complexes and urged businesses to have staff work from home or live at their job on Friday. In response to citizens’ fears about possible food shortages, a Xian government official stated on Saturday that the declaration did not represent a lockdown and also that the city would not enforce one.

On Saturday, the mayor of Suzhou, near Shanghai, said that all employees who are able to work from home must do so, and that residential complexes and business campuses should avoid allowing individuals and cars to enter without permission. In its most major outbreak, it has recorded more than 500 infections. Shanghai, which has been at the epicentre of China’s ongoing COVID outbreak since early March, reported a new high of 3,590 symptomatic cases and 19,923 asymptomatic cases on Saturday. The number of asymptomatic cases increased marginally from 19,872 the day before. Despite the fact that most of the city’s 25 million citizens are still under lockdown, its case total accounts for the great majority of cases nationwide. China’s “dynamic clearing” programme tries to contain rare outbreaks as rapidly as possible. The method has been the optimal choice at this moment based on China’s existing epidemic condition.

However, in a letter posted on the consulate’s website on Saturday, Japan’s consul general in Shanghai urged the local authorities to address the concerns of Japanese firms.

In recent weeks, domestic support for a zero-COVID policy has eroded as virus-related restrictions have resulted in food shortages, family separations, lost income, and economic hardship.

Disruptions In The Supply Chain

According to analysts, widespread risks are likely to cause delays in shipments from companies such as Apple this year, putting a strain on the country’s economic growth rate.

The amount of cash that banks must maintain as reserves was slashed by China’s central bank on Friday evening, attempting to cushion a steep slowdown in growth, albeit the drop was smaller than widely predicted. Analysts at Goldman Sachs advocated more policy easing. Policymakers may lean toward deploying additional fiscal measures (such as accelerating the development of large infrastructure projects) and focused monetary stimulus (like relending & rediscounting) as the key policy levers going forward, Goldman Sachs wrote in a note.

Only personnel with valid passes, health codes, and proof of negative COVID tests will be allowed to leave the Zhengzhou economic zone during the two-week period, local councils said in a post on an official WeChat instant messaging account, though “special vehicles” will be free to travel normally for work reasons.

On April 15, China had 24,791 new cases of coronavirus, with 3,896 of them being symptomatic and 20,895 of them not, according to the National Health Commission.

Previous Post

Covaxin Phase 2 And 3 Trials Have Been Paused By The USFDA

Next Post

Is Herd Immunity To COVID-19 Possible Or Is It Just A Farce?

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post
Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

Is Herd Immunity To COVID-19 Possible Or Is It Just A Farce?

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In